These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Falade-Nwulia O; Suarez-Cuervo C; Nelson DR; Fried MW; Segal JB; Sulkowski MS Ann Intern Med; 2017 May; 166(9):637-648. PubMed ID: 28319996 [TBL] [Abstract][Full Text] [Related]
5. [Hepatitis C virus: 25 years-old, the end?]. Pol S Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503 [TBL] [Abstract][Full Text] [Related]
6. The hepatitis C revolution part 1: antiviral treatment options. Thiagarajan P; Ryder SD Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328 [TBL] [Abstract][Full Text] [Related]
7. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. Bailly F; Pradat P; Virlogeux V; Zoulim F Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282 [TBL] [Abstract][Full Text] [Related]
8. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. Gurusamy KS; Tsochatzis E; Toon CD; Xirouchakis E; Burroughs AK; Davidson BR Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006803. PubMed ID: 24307460 [TBL] [Abstract][Full Text] [Related]
10. Interferon free therapy with direct acting antivirals for HCV. Asselah T; Marcellin P Liver Int; 2013 Feb; 33 Suppl 1():93-104. PubMed ID: 23286852 [TBL] [Abstract][Full Text] [Related]
11. How to optimize current treatment of genotype 2 hepatitis C virus infection. Marciano S; Gadano AC Liver Int; 2014 Feb; 34 Suppl 1():13-7. PubMed ID: 24373073 [TBL] [Abstract][Full Text] [Related]
12. Faldaprevir for the treatment of genotype-1 hepatitis C virus. Agarwal K; Barnabas A Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):277-88. PubMed ID: 25633983 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection. Ahmed OA; Kaisar HH; Hawash N; Samir H; Shabana SST; Hassan A Fouad M; Rizk F; Abd-Elsalam S Infect Disord Drug Targets; 2017; 17(2):95-100. PubMed ID: 28413993 [TBL] [Abstract][Full Text] [Related]
14. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety. Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117 [TBL] [Abstract][Full Text] [Related]
15. What is the future of ribavirin therapy for hepatitis C? Koh C; Liang TJ Antiviral Res; 2014 Apr; 104():34-9. PubMed ID: 24468277 [TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Liu CH; Liu CJ; Lin CL; Liang CC; Hsu SJ; Yang SS; Hsu CS; Tseng TC; Wang CC; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH Clin Infect Dis; 2008 Nov; 47(10):1260-9. PubMed ID: 18834319 [TBL] [Abstract][Full Text] [Related]
17. Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review. Mantry PS; Pathak L Expert Rev Anti Infect Ther; 2016; 14(2):157-65. PubMed ID: 26567871 [TBL] [Abstract][Full Text] [Related]
18. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042 [TBL] [Abstract][Full Text] [Related]
19. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals. Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374 [TBL] [Abstract][Full Text] [Related]
20. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]